Literature DB >> 26930533

Preschool outcomes following prenatal serotonin reuptake inhibitor exposure: differences in language and behavior, but not cognitive function.

Katrina C Johnson1, Alicia K Smith, Zachary N Stowe, D Jeffrey Newport, Patricia A Brennan.   

Abstract

OBJECTIVE: To test the hypothesis that prenatal exposure to serotonin reuptake inhibitors (SRIs) is associated with language and behavioral outcomes in preschool-aged children, while accounting for confounds such as concomitant exposures and maternal mental illness.
METHOD: An observational, prospective, longitudinal study of mental illness in pregnancy was conducted at a university-based women's mental health clinic (April 2010-November 2012). A sample of 178 mother-child dyads participated in a laboratory visit at preschool age (2.5-5.5 years). The majority of women (87%) received psychotropic medication during pregnancy. Psychiatric status (based on DSM-IV), other medication use, and substance use were serially assessed and tested as confounds. Primary outcome measures included standardized measures of expressive language and cognitive function and mother and alternate caregiver ratings of child behavior problems, including the Pervasive Developmental Disorders (PDD) subscale of the Child Behavior Checklist.
RESULTS: Linear regression analyses revealed that, after controlling for relevant covariates, expressive language scores from the Test of Early Language Development, 3rd edition, were negatively associated with prenatal SRI exposure (β = -0.15, t = -2.41), while the PDD behavioral problems subscales completed by alternate caregivers and mothers were positively associated with prenatal SRI exposure (β = 0.17, t = 2.01; β = 0.16, t = 2.00, respectively). Cognitive function, measured using the Differential Ability Scales, 2nd edition, was not associated with any medication exposures.
CONCLUSIONS: The current data suggest a small but significant association between prenatal SRI exposure and preschool outcomes, including expressive language and behavior problems. These data corroborate data from recent, population-based studies, although overall, published findings are mixed. Replication and identification of moderating risk factors are needed to understand potential clinical implications. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26930533      PMCID: PMC5512164          DOI: 10.4088/JCP.14m09348

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  46 in total

1.  Increasing use of antidepressants in pregnancy.

Authors:  William O Cooper; Mary E Willy; Stephen J Pont; Wayne A Ray
Journal:  Am J Obstet Gynecol       Date:  2007-06       Impact factor: 8.661

2.  Genetic heritability and shared environmental factors among twin pairs with autism.

Authors:  Joachim Hallmayer; Sue Cleveland; Andrea Torres; Jennifer Phillips; Brianne Cohen; Tiffany Torigoe; Janet Miller; Angie Fedele; Jack Collins; Karen Smith; Linda Lotspeich; Lisa A Croen; Sally Ozonoff; Clara Lajonchere; Judith K Grether; Neil Risch
Journal:  Arch Gen Psychiatry       Date:  2011-07-04

3.  Maternal depression and anxiety differentially impact fetal exposures during pregnancy.

Authors:  D Jeffrey Newport; Shuang Ji; Qi Long; Bettina T Knight; Elizabeth B Zach; Elizabeth N Smith; Natalie J Morris; Zachary N Stowe
Journal:  J Clin Psychiatry       Date:  2011-11-29       Impact factor: 4.384

Review 4.  Perinatal risks of untreated depression during pregnancy.

Authors:  Lori Bonari; Natasha Pinto; Eric Ahn; Adrienne Einarson; Meir Steiner; Gideon Koren
Journal:  Can J Psychiatry       Date:  2004-11       Impact factor: 4.356

Review 5.  Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review.

Authors:  Salvatore Gentile; Megan Galbally
Journal:  J Affect Disord       Date:  2010-03-19       Impact factor: 4.839

6.  Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

Authors:  Marian K Bakker; Pieternel Kölling; Paul B van den Berg; Hermien E K de Walle; Lolkje T W de Jong van den Berg
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

7.  Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

Authors:  Tim F Oberlander; Shaila Misri; Colleen E Fitzgerald; Xanthoula Kostaras; Dan Rurak; Wayne Riggs
Journal:  J Clin Psychiatry       Date:  2004-02       Impact factor: 4.384

8.  Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay.

Authors:  Rebecca A Harrington; Li-Ching Lee; Rosa M Crum; Andrew W Zimmerman; Irva Hertz-Picciotto
Journal:  Pediatrics       Date:  2014-04-14       Impact factor: 7.124

9.  Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency.

Authors:  P B Pennell; L Peng; D J Newport; J C Ritchie; A Koganti; D K Holley; M Newman; Z N Stowe
Journal:  Neurology       Date:  2007-11-28       Impact factor: 9.910

10.  Antidepressant exposure in pregnancy and risk of autism spectrum disorders.

Authors:  Merete Juul Sørensen; Therese Koops Grønborg; Jakob Christensen; Erik Thorlund Parner; Mogens Vestergaard; Diana Schendel; Lars Henning Pedersen
Journal:  Clin Epidemiol       Date:  2013-11-15       Impact factor: 4.790

View more
  9 in total

Review 1.  A role for the serotonin reuptake transporter in the brain and intestinal features of autism spectrum disorders and developmental antidepressant exposure.

Authors:  Kara Gross Margolis
Journal:  J Chem Neuroanat       Date:  2017-02-14       Impact factor: 3.052

2.  Prenatal antidepressant exposures and gastrointestinal complaints in childhood: A gut-brain axis connection?

Authors:  Amy L Salisbury; George D Papandonatos; Laura R Stroud; Alicia K Smith; Patricia A Brennan
Journal:  Dev Psychobiol       Date:  2020-03-13       Impact factor: 3.038

3.  Perceptual interference processing in preschool children, with and without prenatal exposure to selective serotonin reuptake inhibitors.

Authors:  Tone Kristine Hermansen; Santeri Yrttiaho; Espen Røysamb; Annika Melinder
Journal:  Psychopharmacology (Berl)       Date:  2016-11-08       Impact factor: 4.530

4.  Animal models of developmental motor disorders: parallels to human motor dysfunction in cerebral palsy.

Authors:  Clarissa F Cavarsan; Monica A Gorassini; Katharina A Quinlan
Journal:  J Neurophysiol       Date:  2019-08-14       Impact factor: 2.714

5.  School-age social behavior and pragmatic language ability in children with prenatal serotonin reuptake inhibitor exposure.

Authors:  Erica L Smearman; Cassandra L Hendrix; Dominika A Winiarski; Katrina C Johnson; Alicia K Smith; Opal Y Ousley; Zachary N Stowe; D Jeffrey Newport; Patricia A Brennan
Journal:  Dev Psychopathol       Date:  2020-02

6.  Long-Term Effects of Intrauterine Exposure to Antidepressants on Physical, Neurodevelopmental, and Psychiatric Outcomes: A Systematic Review.

Authors:  Anna-Sophie Rommel; Veerle Bergink; Xiaoqin Liu; Trine Munk-Olsen; Nina Maren Molenaar
Journal:  J Clin Psychiatry       Date:  2020-05-12       Impact factor: 4.384

7.  Maternal prenatal depression and epigenetic age deceleration: testing potentially confounding effects of prenatal stress and SSRI use.

Authors:  Brooke G McKenna; Cassandra L Hendrix; Patricia A Brennan; Alicia K Smith; Zachary N Stowe; D Jeffrey Newport; Anna K Knight
Journal:  Epigenetics       Date:  2020-07-24       Impact factor: 4.528

8.  Association of Maternal Antidepressant Prescription During Pregnancy With Standardized Test Scores of Danish School-aged Children.

Authors:  Jakob Christensen; Betina B Trabjerg; Yuelian Sun; Julie Werenberg Dreier
Journal:  JAMA       Date:  2021-11-02       Impact factor: 56.272

9.  Maternal Trauma Exposure and Childhood Anxiety Outcomes: Examining Psychosocial Mechanisms of Risk.

Authors:  Brittany A Robinson; Cassandra L Hendrix; H Sloan Krakovsky; Alicia K Smith; Patricia A Brennan
Journal:  J Abnorm Child Psychol       Date:  2019-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.